NCT07022704

Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial

The Influence of Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial: a Prospective Observational Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 35 (estimated)
• Sponsor: Cairo University · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial

Detailed description

doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound

Conditions

• COPD
• Mechanical Ventilation
• Weaning From Mechanical Ventilation

Interventions

Type	Name	Description
DRUG	Doxapram	Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT

Timeline

• Start date: 2025-06-22
• Primary completion: 2025-10-30
• Completion: 2025-11-01
• First posted: 2025-06-15
• Last updated: 2025-06-26

Locations

1 site across 1 country: Egypt